Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab long-term safety in severe familial hypercholesterolemia (TAUSSIG)
NCT01624142Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2012
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of evolocumab in familial hypercholesterolemia (FH), sponsored by Amgen. Started Jun 2012; status: completed.
02
Drugs
evolocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT01624142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624142.